-
CompareAdipogenic Induction MediumCatalog #: PT-3102B
Induction Medium for adipogenic differentiation of mesenchymal stem cells
Sales unit: each -
CompareAD1 4D-Nucleofector™ Y KitCatalog #: V4YP-1A24For adherent electroporation of primary cells, e.g. neuronal or endothelial cells, when working with the 4D-NucleofectorTM Y Unit.Sales unit: items
-
CompareHuman Mesenchymal Stem Cell (hMSC) Osteogenic Differentiation Medium BulletKitTMCatalog #: PT-3002
Culture system containing required basal medium and supplements for hMSC osteogenic differentiation
Sales unit: kit -
CompareHuman Mesenchymal Stem Cell (hMSC) Adipogenic Differentiation Medium BulletKitTMCatalog #: PT-3004
Culture system containing basal medium and supplements required for maintenance and induction of hMSC adipogenic differentiation
Sales unit: kit -
ComparehMSC Adipogenic Induction SingleQuots™ KitCatalog #: PT-4135
SingleQuotsTM Kit for adipogenic differentiation of mesenchymal stem cells
Sales unit: each -
CompareNPMM™ Neural Progenitor Maintenance Medium BulletKit™Catalog #: CC-3209Culture system containing PBMTM Neural Progenitor Basal Medium (CC-3210), NPMMTM Maintenance Media SingleQuotsTM (CC-4241) and Neural Progenitor Supplement SingleQuotsTM (CC-4242) required for growth and differentiation of neural progenitor cells
Sales unit: kit -
CompareStellate Cells, Human Cryopreserved, 0.2 Million CellsCatalog #: HUCLS-200K
Low passage stellate cells dervied from human liver tissue containing 200,000 cells/vial.
Do you need a modified version of this cell product, such as different vialing sizes, or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Sales unit: Ampule -
CompareStellate Cells, Human Cryopreserved, 1 Million CellsCatalog #: HUCLS-1M
Low passage stellate cells dervied from human liver tissue containing 1 million cells/vial.
Do you need a modified version of this cell product, such as different vialing sizes, or isolations from special donors or species? Contact Lonza CellBio Services to discuss custom isolation, expansion, and testing options for your research
Sales unit: Ampule -
CompareToxiLight™ Non-Destructive Cytotoxicity BioAssay Kit with Plates, 500 TestCatalog #: LT17-217
ToxiLightTM Assay Kit including (5) 96-Well Clear Bottom, White Walled Plates, 500 Tests
Sales unit: each -
CompareToxiLight™ Non-Destructive Cytotoxicity BioAssay Kit, 1000 TestCatalog #: LT07-117
Assay designed to measure toxicity in mammalian cells and cell lines in culture.
Sales unit: each
-
Natural Killer Cells InfographicNatural Killer cells have an innate ability to recognize and destroy non-self cells.
-
3D Natural Killer Cell-mediated Cytotoxicity AssayLonza White Paper
-
3D Natural Killer (NK) Cell-mediated Cytotoxicity (CMC) Assay -
Natural Killer (NK) Cell Expansion, Activation and Cytotoxicity AssayProtocol instructions
-
Therapeutic Approaches to Enhance Natural Killer Cell Cytotoxicity: The Force AwakensPoster published by Nature Reviews Drug Discovery, sponsored by Lonza. Natural killer (NK) cells are emerging as attractive candidates for new immunotherapeutic approaches. The poster shows the approaches to NK cell tumor targeting.
-
Transfection Protocol for Human NK Cells - Nucleofector™ I/II/2b Device SeriesInstructions of use for transfection of human natural killer cells with Nucleofector™ 1/2 Devices (incl. 1, 2b, 2N, 2S)
-
An Innovative, Highly Efficient Method for Transfecting Large Quantities of Primary Human T-cellsA strong need exists for improved cancer treatment options. Lonza's approach relies on genetically modified, patient-derived cells like T-cells or natural killer cells which express chimeric antigen receptors (CAR) targeting cancer cells.
-
NK Cell Assay using 3D Bioprinted Tumor ModelsThis white paper describes an ex vivo assay for NK cell killing activity in a 3D bioprinted cervical cancer tumor model.
-
TechSheet - Poietics™ Human Immune System CellsTechnical Product Information Sheet
-
CAR T cells in Cancer TherapyA poster developed by Nature Reviews in conjunction with Lonza to present CAR T cells in cancer therapy. This poster demonstrates the recognition of tumor peptides by T cells, CAR T cell manufacturing, the types of chimeric antigen receptors and a timeline of CAR development over more than 30 years.